Thoracic Cancer · 2019 · 51 citations · 14 references
MedicineOncologyRadiation OncologyImmunotherapyThoracic OncologyThoracic Radiation OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationRadiation TherapyImmune Checkpoint Blockade CombinationsImmune Checkpoint Combination TherapyImmune Checkpoint Inhibitor TherapyNon-small Cell Lung Cancer ImmunotherapyNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentRadiation-enhanced ImmunotherapyTherapeutic Efficacy Assessment
BACKGROUND: It remains unclear why radiation clinically provides a synergistic effect when combined with immune checkpoint inhibitors such as nivolumab. The purpose of our study was to retrospectively evaluate whether the therapeutic efficacy of nivolumab is improved as a result of a history of radiotherapy (RT) in patients with previously treated advanced non-small cell lung cancer (NSCLC). METHODS: From February 2016 to December 2017, 124 consecutive patients were administered nivolumab for pretreated advanced NSCLC. The patients were divided into RT and non-RT groups. RESULTS: Sixty-six (53%) of the 124 patients had been administered RT before the initiation of nivolumab, 52 (42%) received extracranial RT, and 40 (32%) were treated with thoracic RT. The median number of nivolumab cycles was 4 (range: 1-43). The overall response rate (ORR) and disease control rate (DCR) of nivolumab in all patients were 28.0% and 58.4%, respectively. The ORR (36.4%) was significantly higher in patients who had received previous RT than in patients who had not received any RT (19%). The therapeutic efficacy of nivolumab was particularly noteworthy in patients with non-adenocarcinoma and squamous cell carcinoma histology administered extracranial RT, with ORRs of 48.3% and 52.6%, and DCRs of 87.1% and 84.2%, respectively. CONCLUSION: Previous RT was an independent prognostic marker of favorable prognosis after nivolumab administration and improved the response rate to nivolumab treatment. Previous RT was clinically identified to have a synergistic effect with nivolumab treatment, increasing the response rate and improving the outcome of patients with advanced NSCLC.
14
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations
Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +15
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2017 · 4.5K citations · Full text
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Liufu Deng, Hua Liang, Byron Burnette et al. · Journal of Clinical Investigation · 2014 · 2.1K citations
Medicine, Immunology, Oncology +17